Sientra Inc (NASDAQ:SIEN) Expected to Post Quarterly Sales of $18.70 Million

Wall Street analysts expect that Sientra Inc (NASDAQ:SIEN) will report sales of $18.70 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sientra’s earnings, with the lowest sales estimate coming in at $18.50 million and the highest estimate coming in at $18.80 million. Sientra posted sales of $17.55 million in the same quarter last year, which would indicate a positive year over year growth rate of 6.6%. The company is expected to announce its next quarterly earnings report on Wednesday, May 13th.

On average, analysts expect that Sientra will report full year sales of $94.07 million for the current fiscal year, with estimates ranging from $93.60 million to $94.60 million. For the next year, analysts anticipate that the company will post sales of $114.03 million, with estimates ranging from $113.40 million to $115.10 million. Zacks’ sales averages are an average based on a survey of research firms that cover Sientra.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Wednesday, March 11th. The medical instruments supplier reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $23.21 million for the quarter, compared to the consensus estimate of $23.20 million. Sientra had a negative net margin of 131.32% and a negative return on equity of 110.93%.

Several equities analysts have weighed in on the stock. Canaccord Genuity lowered their price target on shares of Sientra from $13.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, March 12th. They noted that the move was a valuation call. Craig Hallum lowered their price target on shares of Sientra from $14.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, March 12th. Maxim Group lowered their price target on shares of Sientra from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, March 12th. Stephens lowered their price target on shares of Sientra from $10.00 to $5.00 and set an “overweight” rating on the stock in a report on Monday, March 23rd. Finally, Zacks Investment Research downgraded shares of Sientra from a “buy” rating to a “hold” rating in a report on Wednesday, March 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $7.43.

In related news, CEO Jeffrey M. Nugent sold 63,557 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $5.91, for a total value of $375,621.87. Following the sale, the chief executive officer now owns 326,896 shares in the company, valued at $1,931,955.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey M. Nugent sold 16,506 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $6.00, for a total transaction of $99,036.00. Following the completion of the sale, the chief executive officer now owns 326,896 shares in the company, valued at approximately $1,961,376. The disclosure for this sale can be found here. Insiders own 13.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in SIEN. Millennium Management LLC increased its position in Sientra by 97,855.6% in the third quarter. Millennium Management LLC now owns 3,242,332 shares of the medical instruments supplier’s stock worth $21,010,000 after purchasing an additional 3,239,022 shares during the last quarter. Monarch Partners Asset Management LLC increased its position in Sientra by 392.7% during the fourth quarter. Monarch Partners Asset Management LLC now owns 634,488 shares of the medical instruments supplier’s stock valued at $5,672,000 after acquiring an additional 505,718 shares during the last quarter. EAM Investors LLC bought a new position in Sientra during the fourth quarter valued at $2,657,000. Assenagon Asset Management S.A. increased its position in Sientra by 75.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 490,974 shares of the medical instruments supplier’s stock valued at $4,389,000 after acquiring an additional 210,702 shares during the last quarter. Finally, EAM Global Investors LLC bought a new position in Sientra during the fourth quarter valued at $1,728,000. Institutional investors own 85.25% of the company’s stock.

NASDAQ:SIEN traded up $0.02 during trading hours on Monday, hitting $1.96. 1,370,313 shares of the stock traded hands, compared to its average volume of 919,180. The company has a quick ratio of 1.67, a current ratio of 2.23 and a debt-to-equity ratio of 0.47. Sientra has a 1 year low of $1.00 and a 1 year high of $9.71. The company has a market cap of $96.98 million, a price-to-earnings ratio of -0.66 and a beta of 1.23. The stock has a 50 day moving average price of $3.60 and a 200 day moving average price of $6.50.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: Coverage Ratio

Get a free copy of the Zacks research report on Sientra (SIEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.